Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCurrent AssetsCurrent Deferred RevenueCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current DebtNotes PayablesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zhengye Biotechnology Holding (ZYBT) Payables (2023 - 2025)

Historic Payables for Zhengye Biotechnology Holding (ZYBT) over the last 3 years, with Q2 2025 value amounting to $17.1 million.

  • Zhengye Biotechnology Holding's Payables changed N/A to $17.1 million in Q2 2025 from the same period last year, while for Jun 2025 it was $17.1 million, marking a year-over-year change of. This contributed to the annual value of $16.3 million for FY2024, which is 1820.68% down from last year.
  • According to the latest figures from Q2 2025, Zhengye Biotechnology Holding's Payables is $17.1 million.
  • In the past 5 years, Zhengye Biotechnology Holding's Payables ranged from a high of $19.6 million in Q4 2023 and a low of $16.3 million during Q4 2024
  • In the last 3 years, Zhengye Biotechnology Holding's Payables had a median value of $17.1 million in 2025 and averaged $17.7 million.
  • The largest annual percentage gain for Zhengye Biotechnology Holding's Payables in the last 5 years was 1663.97% (2024), contrasted with its biggest fall of 1663.97% (2024).
  • Over the past 3 years, Zhengye Biotechnology Holding's Payables (Quarter) stood at $19.6 million in 2023, then fell by 16.64% to $16.3 million in 2024, then rose by 4.6% to $17.1 million in 2025.
  • Its last three reported values are $17.1 million in Q2 2025, $16.3 million for Q4 2024, and $19.6 million during Q4 2023.